Nanjing Vazyme Biotech Co Ltd (688105) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has a cash flow conversion efficiency ratio of 0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥75.30 Million ≈ $11.02 Million USD) by net assets (CN¥3.84 Billion ≈ $562.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Nanjing Vazyme Biotech Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Nanjing Vazyme Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Nanjing Vazyme Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Nanjing Vazyme Biotech Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Nanjing Vazyme Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GKG Precision Machine Co. Ltd. A
SHE:301338
|
-0.015x |
|
Droneshield Ltd
AU:DRO
|
-0.013x |
|
Anhui Andeli Department Store Co Ltd
SHG:603031
|
0.085x |
|
Hainan Drinda Automotive Trim Co Ltd
SHE:002865
|
-0.246x |
|
Guangdong Yizumi Precision Machinery Co Ltd
SHE:300415
|
-0.008x |
|
Changchun UP Optotech Co Ltd
SHE:002338
|
-0.020x |
|
QCR Holdings Inc
NASDAQ:QCRH
|
0.004x |
|
Grupo Televisa S.A.B
MX:TLEVISACPO
|
0.100x |
Annual Cash Flow Conversion Efficiency for Nanjing Vazyme Biotech Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Nanjing Vazyme Biotech Co Ltd (688105) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.79 Billion ≈ $554.78 Million |
CN¥233.16 Million ≈ $34.12 Million |
0.061x | +2605.02% |
| 2024-12-31 | CN¥3.94 Billion ≈ $577.07 Million |
CN¥-9.68 Million ≈ $-1.42 Million |
-0.002x | -104.99% |
| 2023-12-31 | CN¥4.03 Billion ≈ $589.61 Million |
CN¥198.40 Million ≈ $29.03 Million |
0.049x | -69.11% |
| 2022-12-31 | CN¥4.61 Billion ≈ $674.90 Million |
CN¥735.17 Million ≈ $107.58 Million |
0.159x | +6.66% |
| 2021-12-31 | CN¥4.13 Billion ≈ $603.95 Million |
CN¥616.80 Million ≈ $90.26 Million |
0.149x | -75.22% |
| 2020-12-31 | CN¥1.33 Billion ≈ $194.97 Million |
CN¥803.55 Million ≈ $117.59 Million |
0.603x | +693.51% |
| 2019-12-31 | CN¥200.02 Million ≈ $29.27 Million |
CN¥15.20 Million ≈ $2.22 Million |
0.076x | +415.63% |
| 2018-12-31 | CN¥166.08 Million ≈ $24.30 Million |
CN¥-4.00 Million ≈ $-585.21K |
-0.024x | +5.92% |
| 2017-12-31 | CN¥150.82 Million ≈ $22.07 Million |
CN¥-3.86 Million ≈ $-564.87K |
-0.026x | -- |
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more